Evidence map›Paper›PMID 40317641›Full record

ArticleInternal medicine journal2025

Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era.

Luani Barge, Steven Tran, Glen Kennedy, David Ritchie, David Gottlieb, Sam Milliken, Andrew Spencer, Duncan Purtill, Travis Perera, Richard Doocey and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Luani BargeDepartment of Haematology, Princess Alexandra Hospital University of Queensland, Brisbane, Queensland, Australia.ORCID 0000-0002-3698-7383
Steven TranDepartment of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
Glen KennedyDepartment of Haematology, Royal Brisbane and Women's Hospital, University of Queensland, Brisbane, Queensland, Australia.
David RitchieDepartment of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
David GottliebDepartment of Haematology, Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia.
Sam MillikenDepartment of Haematology, St Vincent's Hospital Sydney, Sydney, New South Wales, Australia.
Andrew SpencerDepartment of Haematology, The Alfred, University of Melbourne, Melbourne, Victoria, Australia.
Duncan PurtillDepartment of Haematology, Fiona Stanley Hospital, Perth, Western Australia, Australia.
Travis PereraWellington Blood and Cancer Centre, Wellington, New Zealand.
Richard DooceyDepartment of Haematology, Auckland City Hospital, Auckland, New Zealand.
Stephen LarsenDepartment of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Andrew ButlerDepartment of Haematology, Christchurch Hospital, Christchurch, New Zealand.ORCID 0000-0002-3031-3492
Peter BardyDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Matthew GreenwoodDepartment of Haematology, Royal North Shore Hospital, Sydney, New South Wales, Australia.ORCID 0000-0002-3667-2613
Simon DurrantDepartment of Haematology, Wesley Hospital, Brisbane, Queensland, Australia.
Cameron CurleyDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Caroline StewartDepartment of Haematology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Constantine TamDepartment of Haematology, The Alfred, University of Melbourne, Melbourne, Victoria, Australia.ORCID 0000-0002-9759-5017
Shalini BalendranDepartment of Haematology, The Alfred, University of Melbourne, Melbourne, Victoria, Australia.
Pietro R Di CiaccioDepartment of Haematology, The Canberra Hospital, Australian National University, Canberra, Australian Capital Territory, Australia.ORCID 0000-0002-9282-8619
Sushrut PatilDepartment of Haematology, The Alfred, University of Melbourne, Melbourne, Victoria, Australia.
Min-Hi HanDepartment of Haematology, Christchurch Hospital, Christchurch, New Zealand.
Nada HamadDepartment of Haematology, St Vincent's Hospital Sydney, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0001-7929-1450

Funding

Leukaemia Foundation
6 · The paper itself

Abstract

backgroundAllogeneic haemopoietic stem cell transplantation (HSCT) is an effective therapy with curative potential for patients with high-risk or relapsed/refractory chronic lymphocytic leukaemia (CLL). There are limited data on the use and outcomes of HSCT in the modern era of CLL treatment.

aimsThe aim of this study was to examine the use of HSCT performed for CLL in Australia and New Zealand, including patients exposed to pathway inhibitors (PIs) prior to transplant.

methodsData were collected through the Australian and New Zealand Transplant and Cellular Therapy Registry for all patients who underwent HSCT for CLL between January 2009 and December 2018. Transplant outcomes were compared between two 5-year time periods: 2009-2013 and 2014-2018.

resultsNinety-four patients underwent HSCT during 2009-2013 and 50 during 2014-2018. There was a significant reduction in non-relapse mortality (NRM) from 42% (95% confidence interval (CI): 31-52) to 23% (95% CI: 12-35, P = 0.02) between the periods; however, overall survival (OS), progression-free survival (PFS) and relapse were unchanged. Within the 2014-2018 cohort, 22 patients were PI exposed prior to transplant. At 3 years, these patients demonstrated a median OS of 54% (95% CI: 35-82), PFS of 44% (95% CI: 27-71), NRM of 25% (95% CI: 8-45) and cumulative incidence of relapse of 32% (95% CI: 14-52). In multivariate analysis, only disease in complete remission at the time of HSCT was associated with improved OS (hazard ratio: 2.54, 95% CI: 1.04-6.18).

conclusionAllogeneic HSCT remains a viable treatment option for select patients with CLL.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Lymphocytic, Chronic, B-CellAdultAgedAustraliaFemaleHumansMaleMiddle AgedNew ZealandRegistriesRetrospective StudiesTransplantation, HomologousTreatment Outcomeallogeneic haemopoietic stem cell transplantationBCL2 inhibitorBruton tyrosine kinase inhibitorchronic lymphocytic leukaemiapathway inhibitor

Identifiers

PMID40317641
PMCPMC12240015

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.